<DOC>
	<DOCNO>NCT00645307</DOCNO>
	<brief_summary>The purpose study Open Label Extension recurrence prevention study evaluate long-term safety tolerability paliperidone ER subject schizophrenia .</brief_summary>
	<brief_title>A 52 Week Open Label Extension Trial Following Recurrence Prevention Study R076477-SCH-301 Evaluate Safety Tolerability Paliperidone ER Subjects With Schizophrenia .</brief_title>
	<detailed_description>The primary objective open-label extension long-term assessment safety tolerability ER OROS paliperidone 3 15 mg/day subject diagnose schizophrenia . In addition , long-term efficacy effect ER OROS paliperidone overall functioning personal social functioning , well quality life , health economics , subjective sleep measure , explore . This open-label extension study follow recurrence prevention study ( R076477-SCH-301 ) open-label run-in/stabilization phase double-blind , placebo-controlled phase . Open-label study drug ( ER OROS paliperidone 3 mg 15 mg/day ) administer 52 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Subjects experience recurrence event double blind phase Study R076477SCH301 Remained recurrence free end doubleblind phase , runin stabilization phase study terminate Who sign informed consent openlabel extension And investigator agree openlabel treatment best interest subject eligible participate openlabel extension Not eligible enter openlabel phase believe significant risk suicidal violent behavior openlabel extension trial Were pregnant receive injection depot antipsychotic since entry precede doubleblind phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>paliperidone</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>